Ratings Johnson & Johnson Santiago S.E.

Equities

JNJ

US4781601046

Real-time Estimate Cboe BZX Other stock markets 12:51:05 06/06/2024 am IST			5-day change	1st Jan Change
146.2 ^USD	-1.38%		0.00%	-6.76%

10:07am	J&J: applies to FDA for expanded indication for Prezcobix	CF
04/06	Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's enterprise value to sales, at 3.95 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JOHNSON & JOHNSON	-6.76%	36TCr	-
ELI LILLY AND COMPANY	+43.26%	75TCr	C+
NOVO NORDISK A/S	+34.11%	61TCr	B
MERCK & CO., INC.	+19.00%	33TCr	B-
ABBVIE INC.	+6.84%	29TCr	C+
ASTRAZENECA PLC	+18.08%	25TCr	B+
ROCHE HOLDING AG	-3.44%	21TCr	A+
NOVARTIS AG	+11.35%	21TCr	B-
PFIZER, INC.	+1.96%	17TCr	C+
AMGEN INC.	+7.12%	16TCr	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes